Cellectis (NASDAQ:CLLS) Issues Quarterly Earnings Results

Key Points

• Cellectis reported a quarterly loss of ($0.24) earnings per share, missing analysts' expectations by $0.09, while also showing a negative return on equity of 62.55% and a net margin of 114.82%.
• Despite the earnings miss, Cellectis’ stock increased by 2.4% to $3.02 during trading, with significant trading volume rising above the average.
• Institutional investor UBS AM raised its stake by 228.4%, now holding approximately 8.50% of the company's shares, amid overall institutional ownership of 63.90% in Cellectis.

Cellectis (NASDAQ:CLLS - Get Free Report) released its quarterly earnings data on Monday. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.09), Zacks reports. The company had revenue of $18.19 million for the quarter, compared to the consensus estimate of $10.07 million. Cellectis had a negative return on equity of 68.05% and a negative net margin of 100.69%.

Cellectis Stock Down 1.7%

Shares of NASDAQ:CLLS traded down $0.05 during midday trading on Friday, hitting $2.62. 82,268 shares of the stock were exchanged, compared to its average volume of 234,687. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.67 and a current ratio of 1.38. Cellectis has a 52-week low of $1.10 and a 52-week high of $3.24. The business's fifty day simple moving average is $1.82 and its two-hundred day simple moving average is $1.56. The company has a market capitalization of $145.34 million, a PE ratio of -3.19 and a beta of 3.03.

Institutional Trading of Cellectis

A hedge fund recently raised its stake in Cellectis stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Cellectis S.A. (NASDAQ:CLLS - Free Report) by 228.4% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,722,664 shares of the biotechnology company's stock after acquiring an additional 3,284,409 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 8.50% of Cellectis worth $5,856,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 63.90% of the company's stock.

Wall Street Analyst Weigh In

CLLS has been the subject of a number of research analyst reports. Wall Street Zen lowered Cellectis from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Barclays reduced their target price on Cellectis from $5.00 to $4.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.